MARKET

PTGX

PTGX

Protagonist
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.82
-0.50
-6.01%
After Hours: 7.82 0 0.00% 16:10 02/27 EST
OPEN
8.20
PREV CLOSE
8.32
HIGH
8.20
LOW
7.68
VOLUME
313.36K
TURNOVER
--
52 WEEK HIGH
16.67
52 WEEK LOW
4.470
MARKET CAP
212.75M
P/E (TTM)
-2.6555
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTGX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTGX stock price target is 20.60 with a high estimate of 29.00 and a low estimate of 17.00.

EPS

PTGX News

More
  • Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 14h ago
  • Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
  • PR Newswire · 02/19 12:00
  • How Does Investing In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Impact The Volatility Of Your Portfolio?
  • Simply Wall St. · 02/11 16:18
  • Key events next week - healthcare
  • Seeking Alpha - Article · 02/07 14:47

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About PTGX

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
More

Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions.